RESUMEN
ABSTRACT: Corrected QT (QTc) interval prolongation has been associated with poor patient prognosis. In this study, we assessed the effects of different drugs and cardiac injury on QTc interval prolongation in patients with coronavirus disease 2019 (COVID-19).The study cohort consisted of 395 confirmed COVID-19 cases from the Wuhan Union Hospital West Campus. All hospitalized patients were treated with chloroquine/hydroxychloroquine (CQ/HCQ), lopinavir/ritonavir (LPV/r), quinolones, interferon, Arbidol, or Qingfei Paidu decoction (QPD) and received at least 1 electrocardiogram after drug administration.Fifty one (12.9%) patients exhibited QTc prolongation (QTcâ≥â470âms). QTc interval prolongation was associated with COVID-19 severity and mortality (both Pâ<â.001). Administration of CQ/HCQ (odds ratio [OR], 2.759; 95% confidence interval [CI], 1.318-5.775; Pâ=â.007), LPV/r (OR, 2.342; 95% CI, 1.152-4.760; Pâ=â.019), and quinolones (OR, 2.268; 95% CI, 1.171-4.392; Pâ=â.015) increased the risk of QTc prolongation. In contrast, the administration of Arbidol, interferon, or QPD did not increase the risk of QTc prolongation. Notably, patients treated with QPD had a shorter QTc duration than those without QPD treatment (412.10 [384.39-433.77] vs 420.86 [388.19-459.58]; Pâ=â.042). The QTc interval was positively correlated with the levels of cardiac biomarkers (creatine kinase-MB fraction [rhoâ=â0.14, Pâ=â.016], high-sensitivity troponin I [rhoâ=â.22, Pâ<â.001], and B-type natriuretic peptide [rhoâ=â0.27, Pâ<â.001]).In conclusion, QTc prolongation was associated with COVID-19 severity and mortality. The risk of QTc prolongation was higher in patients receiving CQ/HCQ, LPV/r, and quinolones. QPD had less significant effects on QTc prolongation than other antiviral agents.
Asunto(s)
Antivirales/efectos adversos , Tratamiento Farmacológico de COVID-19 , COVID-19/mortalidad , Síndrome de QT Prolongado/mortalidad , SARS-CoV-2 , Anciano , COVID-19/virología , Cloroquina/efectos adversos , Quimioterapia Combinada , Medicamentos Herbarios Chinos/efectos adversos , Electrocardiografía , Femenino , Mortalidad Hospitalaria , Hospitalización/estadística & datos numéricos , Humanos , Hidroxicloroquina/efectos adversos , Indoles/efectos adversos , Interferones/efectos adversos , Síndrome de QT Prolongado/inducido químicamente , Lopinavir/efectos adversos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Quinolonas/efectos adversos , Estudios Retrospectivos , Ritonavir/efectos adversos , Índice de Severidad de la EnfermedadRESUMEN
BACKGROUND: Coronavirus disease 2019 (COVID-19) continues to impact populations around the globe. Information regarding the incidences and implications of arrhythmias in COVID-19 is limited. METHODS: A total of 463 patients with COVID-19 and who had at least one electrocardiogram recording from February 1 to March 19, 2020, in Wuhan Union Hospital were enrolled in the study. RESULTS: Arrhythmias occurred in 85 of 463 (18.4%) patients: atrial arrhythmias in 10.2%, junctional arrhythmias in 0.2%, ventricular arrhythmias in 3.5%, and conduction block in 7.3%. Compared with patients without arrhythmias, those with arrhythmias had higher mortality, both during the time from symptom onset (p < 0.001) and from admission to follow-up (p < 0.001). The frequencies of severe COVID-19 (44.7% vs. 21.2%; p < 0.001) and death (25.9% vs. 10.1%; p < 0.001) were higher in patients with arrhythmias than in those without arrhythmias. Atrial arrhythmias and ventricular arrhythmias could predict severity and mortality, their odds ratios (OR) were 4.45 (95% confidence interval [CI] 2.35 to 8.40), 5.80 (95% CI 1.89 to 17.76) respectively for severity, and were 3.51 (95% CI 1.74 to 7.08), 3.41 (95% CI 1.13 to 10.24) respectively for mortality. High levels of interleukin-6 (IL-6) and IL-10 were associated with the occurrence of arrhythmias (all p < 0.05). CONCLUSION: Arrhythmias were significantly associated with COVID-19 severity and mortality. Atrial arrhythmia was the most frequent arrhythmia type. IL-6 and IL-10 levels can predict the risk of arrhythmias in COVID-19 patients.
Asunto(s)
Arritmias Cardíacas/epidemiología , COVID-19/complicaciones , Anciano , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/virología , China/epidemiología , Electrocardiografía , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de RiesgoAsunto(s)
Betacoronavirus , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/mortalidad , Hospitalización/tendencias , Neumonía Viral/sangre , Neumonía Viral/mortalidad , Troponina I/sangre , Anciano , Biomarcadores/sangre , COVID-19 , Infecciones por Coronavirus/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Mortalidad/tendencias , Pandemias , Neumonía Viral/diagnóstico , Valor Predictivo de las Pruebas , SARS-CoV-2RESUMEN
In late December 2019, COVID-19 was firstly recognized in Wuhan, China and spread rapidly to all of the provinces of China. The West Campus of Wuhan Union Hospital, the designated hospital to admit and treat the severe and critically ill COVID-19 cases, has treated a large number of such patients with great success and obtained lots of valuable experiences based on the Chinese guideline (V7.0). To standardize and share the treatment procedures of severe and critically ill cases, Wuhan Union Hospital has established a working group and formulated an operational recommendation, including the monitoring, early warning indicators, and several treatment principles for severe and critically ill cases. The treatment experiences may provide some constructive suggestions for treating the severe and critically ill COVID-19 cases all over the world.